文献速递基础与转化研究新药、器械与细胞基因治疗研发

精神分裂症:病理生理学、管理与精准医学进展

Schizophrenia: advances in pathophysiology, management, and precision medicine.
PubMed 文献 · BMJ · 2026-08-28

精神分裂症多在青少年晚期或成年早期起病,由遗传与环境因素共同作用,具有神经发育意义。临床管理包括药物与非生物干预,但生物异质性阻碍新药研发。从机制驱动精准医学角度重新构建精神分裂症概念、基于生物学特征分层患者并积累客观生物标志物,是未来管理进步的关键。

要点

  • 药物干预可改善阳性症状并预防复发进展。
  • 心理社会与认知干预有助功能改善和早期精神病管理。
  • 机制驱动精准医学需按生物学特征分层患者并积累客观生物标志物。

核心结论

  • 基于精准医学框架,精神分裂症管理的进一步进步值得期待。

研究设计与样本

  • 本文为综述,围绕精神分裂症的病理生理学、临床管理与精准医学进展进行论述。

主要发现

  • 精神分裂症由多种遗传与环境因素共同导致,具有显著神经发育意义。
  • 药物干预可改善阳性症状并预防复发所致疾病进展。
  • 心理社会与认知干预有助功能改善、复发预防和早期精神病管理。
  • 神经调控与数字健康干预等新干预仍在研究中。
  • 生物异质性患者群体及仅凭临床操作标准定义疾病,阻碍新治疗策略尤其是药物研发。

临床怎么用

  • 临床管理应综合生物与非生物干预,药物改善阳性症状并预防复发。
  • 心理社会与认知干预用于功能改善、复发预防和早期精神病管理。
  • 未来方向为按生物学特征分层患者并积累客观生物标志物。

局限性

  • 精神分裂症患者群体生物学异质,疾病仅由临床操作标准定义,阻碍新药等治疗策略。
  • 神经调控与数字健康干预等新干预仍处于研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schizophrenia is a common and severe mental condition with onset usually in late adolescence and young adulthood. Schizophrenia is caused by a combination of multiple genetic and environmental factors with significant neurodevelopmental implications. Advances in the clinical management of schizophrenia include biological and non-biological treatments. Drug interventions can ameliorate positive symptoms and prevent the progression of disease due to relapses. Non-biological approaches such as psychosocial and cognitive interventions can help functional improvement, relapse prevention, and early stage psychosis management, and new interventions such as neuromodulation and digital health interventions are still under investigation. Despite these advances, novel therapeutic strategies, particularly drugs, are hampered by a biologically heterogeneous population of patients with schizophrenia, a condition defined only by clinical operational criteria. Reconsidering the construct of schizophrenia from the viewpoint of mechanism driven precision medicine will be important, with stratification of patients on the basis of their biological characteristics. The first step towards this goal is to accumulate objective biomarkers for schizophrenia. On the basis of the framework of precision medicine, further advancement in the management of schizophrenia is expected.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Sawa A, Chiappelli J, Hamrah OP, et al. Schizophrenia: advances in pathophysiology, management, and precision medicine. BMJ. 2026. PMID: 42665310. doi:10.1136/bmj-2026-635470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。